Research Topics
Species | L LicitraSummaryAffiliation: Istituto Nazionale Tumori Country: Italy Publications
| Collaborators
|
Detail Information
Publications
Targeted therapy in head and neck cancerLisa Licitra
Head and Neck Cancer Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, Italy
Curr Opin Otolaryngol Head Neck Surg 19:132-7. 2011..Due to the unique multidisciplinary needs of the disease, it is of paramount importance that physicians who treat HNC are aware of the evolving changes that research is offering...
Human papillomavirus in HNSCC: a European epidemiologic perspectiveLisa Licitra
Head and Neck Medical Oncology Unit, Fondazione IRCCS, Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy
Hematol Oncol Clin North Am 22:1143-53, vii-viii. 2008..Three-year survival rates improved more in human papillomavirus-related than unrelated cancer sites, and women had better rates of survival than men...
High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinomaLisa Licitra
Head and Neck Cancer Medical Oncology Unit, Medical Statistics and Biometry, Department of Head and Neck Surgery, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
J Clin Oncol 24:5630-6. 2006..To which extent the viral integration by itself, and/or the associated wild-type (wt) TP53 status, and/or a functional p16 contribute to prognosis is unclear...
Advances in the changing patterns of aetiology of head and neck cancersLisa Licitra
Head and Neck Cancer Medical Oncology Unit, Cancer Medicine Department, Istituto Nazionale Tumori, Milan, Italy
Curr Opin Otolaryngol Head Neck Surg 14:95-9. 2006..In fact, a review of the most recent literature shows interesting advances in molecular epidemiology...
A multidisciplinary approach to squamous cell carcinomas of the head and neck: what is new?Lisa Licitra
Head and Neck Cancer Medical Oncology Unit, Cancer Medicine Department, Istituto Nazionale Tumori, Milan, Italy
Curr Opin Oncol 18:253-7. 2006..Due to the complexity of the disease the multidisciplinary approach needs also a multidisciplinary knowledge which this review tries to summarize...
Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinomaL Licitra
Medical Oncology Department, Head and Neck Unit, Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy
J Clin Oncol 22:4901-6. 2004..To assess the role of TP53 status in predicting pathologic complete remission after primary chemotherapy in patients with ethmoidal intestinal-type adenocarcinoma (ITAC)...
Is there still a role for neoadjuvant chemotherapy in head and neck cancer?L Licitra
Medical Oncology Unit, Head and Neck Department, Istituto Nazionale Tumori, Milan, Italy
Ann Oncol 15:7-11. 2004..This article reviews current indications for neoadjuvant chemotherapy in advanced head and neck cancer. Implications for current and future research are discussed...
Primary chemotherapy followed by anterior craniofacial resection and radiotherapy for paranasal cancerL Licitra
Unit of Medical Oncology A, Istituto Nazionale Tumori, Milan, Italy
Ann Oncol 14:367-72. 2003..To study prospectively the activity of primary chemotherapy with cisplatin, fluorouracil and leucovorin (PFL) in patients with paranasal cancer receiving surgery and postoperative radiotherapy...
Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trialLisa Licitra
Istituto Nazionale Tumori, Milan, Italy
J Clin Oncol 21:327-33. 2003..Here we repeat the results of a randomized, multicenter trial enrolling patients with a resectable, stage T2-T4 (> 3 cm), N0-N2, M0 untreated, squamous cell carcinoma of the oral cavity...
Multikinase inhibitors in thyroid cancerLisa Licitra
Head and Neck Cancer Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, Milan, Italy
Eur J Cancer 46:1012-8. 2010..To date no drug has proved to prolong survival, as such none of these agents has been approved...
Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer: an Italian validation studyR Granata
Head and Neck Cancer Medical Oncology Unit, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Ann Oncol 23:1832-7. 2012..Recently, three groups with different outcomes were identified based on HPV status, smoking history and tumor stage. Our objective was to validate this model using a single-institutional retrospective database...
Biweekly paclitaxel and cisplatin in patients with advanced head and neck carcinoma. A phase II trialL Licitra
Division of Medical Oncology, Istituto Nazionale Tumori, Milan, Italy
Ann Oncol 8:1157-8. 1997..Cisplatin is an active drug in head and neck cancer. Paclitaxel seems a promising drug. This article reports a phase II assessment of the combination of the two...
Docetaxel, cisplatin and 5-fluorouracil-based induction chemotherapy followed by intensity-modulated radiotherapy concurrent with cisplatin in locally advanced EBV-related nasopharyngeal cancerP Bossi
Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Via Venezian 1, Milan, Italy
Ann Oncol 22:2495-500. 2011....
TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinomaFederica Perrone
Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milano, Italy
J Clin Oncol 28:761-6. 2010....
Optimizing approaches to head and neck cancer. Metastatic head and neck cancer: new optionsL Licitra
Head and Neck Medical Oncology Unit, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Ann Oncol 19:vii200-3. 2008
Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II studyL D Locati
Head and Neck Cancer Medical Oncology Unit, Cancer Medicine Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, Milan, Italy
Oral Oncol 45:574-8. 2009..In RMSGCs further evaluations of EGFR targeting agents are advisable and should take place by appropriate tumor biological selection, differentiating ACC from non-ACC...
A new classification for malignant tumors involving the anterior skull baseG Cantu
Unit of Cranio Maxillo Facial Surgery, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
Arch Otolaryngol Head Neck Surg 125:1252-7. 1999..To propose our clinical classification of malignant ethmoid tumors and to compare it with the last American Joint Committee on Cancer (AJCC)-Union Internationale Contre le Cancer (UICC) classification, published in 1997...
Biological markers as indicators of pathological response to primary chemotherapy in oral-cavity cancersA Costa
Oncologia Sperimentale C, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
Int J Cancer 79:619-23. 1998..02). This interim analysis appears to indicate that some biofunctional markers can provide information on pathological response to PCT and could help in understanding treatment efficacy at a cellular level...
Biological agents in head and neck cancerL Licitra
Istituto Nazionale dei Tumori, Head and Neck Medical Oncology Unit, Milan, Italy
Ann Oncol 17:x45-8. 2006
Treatment of cancer of the base of the tongue and glosso-epiglottic region: a multicenter Italian survey. GLOCC Group. Gruppo di Lavoro in Oncologia Cervico CefalicaC Grandi
Division of Otorhinolaryngology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
Tumori 86:215-23. 2000..The purpose of our study was to evaluate the results of treatment in a large series of patients from 18 Italian institutions in relation to the main treatment adopted...
TP53, p14ARF, p16INK4a and H-ras gene molecular analysis in intestinal-type adenocarcinoma of the nasal cavity and paranasal sinusesFederica Perrone
Unit of Experimental Molecular Pathology, Department of Pathology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
Int J Cancer 105:196-203. 2003..Given the important role that these genes play in cell growth control and apoptosis, the knowledge of ITAC genetic profile may be helpful in selecting more tailored treatments...
Head and neck tumors other than squamous cell carcinomaLisa Licitra
Head and Neck Department, Medical Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
Curr Opin Oncol 16:236-41. 2004..A multidisciplinary team treatment plan is needed, in particular for skull base-located tumors. Salivary gland cancer displays several molecular targets that need to be investigated further...
Head and neck cancerL Licitra
Head and Neck Cancer Medical Oncology Unit, Cancer Medicine Department, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
Ann Oncol 15:iv267-73. 2004
Adenocarcinoma of ethmoid sinus: an occupational diseaseG Bimbi
Head and Neck Surgery Department, National Cancer Institute, Milan, Italy
Acta Otorhinolaryngol Ital 24:199-203. 2004..No significant correlation was observed between exposure and either non-ethmoidal sinonasal neoplasms or ethmoidal tumours other than adenocarcinomas...
Role of EGFR family receptors in proliferation of squamous carcinoma cells induced by wound healing fluids of head and neck cancer patientsL Licitra
Head and Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
Ann Oncol 22:1886-93. 2011..We studied the impact of processes triggered by HNSCC surgery in stimulating both residual tumor cells [demonstrated to overexpress epidermal growth factor receptor (EGFR)], and premalignant cells surrounding the resected lesion...
Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME studyL Licitra
Division of Medical Oncology, Istituto Nazionale Tumori, Milan, Italy
Ann Oncol 22:1078-87. 2011..The aim of this investigation was to evaluate elevated tumor EGFR gene copy number as a predictive biomarker in EXTREME study patients...
Effects of treatment intensification on acute local toxicity during radiotherapy for head and neck cancer: prospective observational study validating CTCAE, version 3.0, scoring systemMauro Palazzi
Unit of Radiotherapy, Istituto Nazionale Tumori, Milan, Italy
Int J Radiat Oncol Biol Phys 70:330-7. 2008..0 (CTCAE v3.0), scoring system...
Biological agents in head and neck cancerPaolo Bossi
Medical Oncology 3 Head and Neck Cancer Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1 20133 Milan, Italy
Expert Rev Anticancer Ther 7:1643-50. 2007..Molecular characteristics and treatment-relevant signaling pathways will be briefly discussed along with the results of the more recent clinical studies that include biological agents...
Oropharyngeal squamous cell carcinoma treated with radiotherapy or radiochemotherapy: prognostic role of TP53 and HPV statusCarlo Fallai
Radiation Oncology Department, Fondazione IRCCS, Istituto Nazionale Tumori, Milan, Italy
Int J Radiat Oncol Biol Phys 75:1053-9. 2009..To study the prognostic value of the TP53 mutation and human papilloma virus (HPV) status in oropharyngeal squamous cell carcinoma (OPSCC)...
Cancer of the nasopharynxLisa Licitra
START Project and Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
Crit Rev Oncol Hematol 45:199-213. 2003..Standard therapeutic option for early stages of NPC is radiation, while an integration of radiation therapy and chemotherapy is indicated in more advanced stages...
Survival from salivary glands adenoid cystic carcinoma in European populationsLaura Ciccolallo
Evaluative Epidemiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, Milan, Italy
Oral Oncol 45:669-74. 2009..Improvements in the disease detection in its early stage and international collaborative research should be encouraged...
p53 codon 72 polymorphisms in human papillomavirus-negative and human papillomavirus-positive squamous cell carcinomas of the oropharynxFederica Perrone
Unit of Experimental Molecular Pathology, Fondazione IRCCS Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
Cancer 109:2461-5. 2007..The TP53 polymorphism, in which an arginine (R) is changed to proline (P) at codon 72, is functionally significant and could therefore be a predisposing genetic defect...
Further improvement in outcomes of nasopharyngeal carcinoma with optimized radiotherapy and induction plus concomitant chemotherapy: an update of the Milan experienceMauro Palazzi
Unit of Radiotherapy, Istituto Nazionale Tumori, Milan, Italy
Int J Radiat Oncol Biol Phys 74:774-80. 2009..To report the outcome of a consecutive series of patients with nonmetastatic nasopharyngeal carcinoma (NPC), focusing on the impact of treatment-related factors...
Regionally advanced nasopharyngeal carcinoma: long-term outcome after sequential chemotherapy and radiotherapyMauro Palazzi
Department of Radiotherapy, National Cancer Institute, Milan, Italy
Tumori 90:60-5. 2004..To evaluate the long-term clinical outcome of 61 patients with regionally advanced nasopharyngeal carcinoma treated with sequential chemotherapy and radiotherapy within a phase II trial...
Which classification for ethmoid malignant tumors involving the anterior skull base?Giulio Cantu
Department of Head and Neck Surgery, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, 20133 Milan, Italy
Head Neck 27:224-31. 2005..The purpose of this study was to compare three systems of classification for malignant ethmoidal tumors in patients undergoing anterior craniofacial resection...
Lung metastasectomy in adenoid cystic carcinoma (ACC) of salivary glandLaura D Locati
Medical Oncology Unit Head and Neck Unit, Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy
Oral Oncol 41:890-4. 2005..Lung metastasectomy provided a prolonged FFP in a high selected subset of patients with ACC. However, if this could be translated into a survival benefit, it is still to be demonstrated...
Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinomaFederica Perrone
Unit of Experimental Molecular Pathology, Department of Pathology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Italy
Clin Cancer Res 12:6643-51. 2006..CONCLUSIONS: Our findings suggest that assessing HPV, TP53, 9p21, and EGFR status may be crucial to finding more tailored and beneficial treatments for oropharyngeal SCCs...
Phenotype-genotype correlation: challenge of intestinal-type adenocarcinoma of the nasal cavity and paranasal sinusesMilo Frattini
Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, 20133 Milan, Italy
Head Neck 28:909-15. 2006..By contrast, both frequency rate and type of inactivation of the APC-beta-catenin pathway differ in the 2 tumors, suggesting different gatekeeper events in the early development of ITAC (p16(INK4a) and TP53) and colorectal cancer (APC)...
Quality of life assessment and clinical decision-makingP Casali
Division of Medical Oncology A, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
Ann Oncol 8:1207-11. 1997..Providing average quality of life scores may be useful, indeed, for population-based health decisions, as are those on resource allocation and those on registration of new drugs...
The burden of rare cancers in EuropeGemma Gatta
Fondazione IRCCS Istituto Nazionale dei Tumori, Dipartimento di Medicina Predittiva e per la Prevenzione, Unità di Epidemiologia Valutativa, Via Venezian, 1, 20133, Milan, Italy
Adv Exp Med Biol 686:285-303. 2010..The burden indicators were estimated and are provided in this chapter...
Primary high-grade mucoepidermoid carcinoma of the minor salivary glands with cutaneous metastases at diagnosisL D Locati
Department of Medical Oncology, Istituto Nazionale Tumori, Via Venezian 1, 20133, Milan, Italy
Oral Oncol 38:401-4. 2002..This feature was associated with a chemoresistant and aggressive behaviour. Differential diagnosis between metastatic MEC and primary skin MEC is essential for therapeutic management and prognosis...
START: a European state-of-the-art on-line instrument for clinical oncologistsP Casali
Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
Ann Oncol 10:769-73. 1999..The goal of instruments such as START is to improve the quality of patient care. In addition, START hopes to make contributions to the methodology by which medical research is transformed into clinical decisions...
Cancer of the anal regionLisa Licitra
START Project, European School of Oncology, Milan, Italy
Crit Rev Oncol Hematol 43:77-92. 2002..Long-term quality of life (QOL) scores are acceptable, with the exception of patients who experience severe anal dysfunction...
Major and minor salivary gland tumorsMarco Guzzo
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Crit Rev Oncol Hematol 74:134-48. 2010..Metastatic disease may be either treated with radiotherapy or palliative chemotherapy, depending on the site of metastases. For highly selected patients the employment of anti-androgen therapy is indicated...
Major and minor salivary glands tumoursLisa Licitra
START Project, European School of Oncology, Viale Beatrice d Este, 37, 20122, Milan, Italy
Crit Rev Oncol Hematol 45:215-25. 2003..Metastastic disease may be either treated with radiotherapy or palliative chemotherapy, depending on the site of metastases...
Forecasting the performance status of head and neck cancer patient treatment by an interval arithmetic pruned perceptronGian Paolo Drago
Istituto per i Circuiti Elettronici-Consiglio Nazionale delle Ricerche, Genova, Italy
IEEE Trans Biomed Eng 49:782-7. 2002..This result should open a new perspective in the clinical approach, by supplying a potential predictive indicator for toxicity...
TP53 mutations in head and neck cancerFederica Perrone
N Engl J Med 358:1194-5; author reply 1195. 2008
Cisplatin and fluorouracil concurrent to radiotherapy in nasopharyngeal cancer: is the schedule compatible?Lisa Licitra
J Clin Oncol 22:377; author reply 377-8. 2004
Is restoring platinum sensitivity the best goal for cetuximab in recurrent/metastatic nasopharyngeal cancer?Lisa Licitra
J Clin Oncol 23:7757-8; author reply 7758-9. 2005
Systemic therapy in the palliative management of advanced salivary gland cancersScott A Laurie
Ottawa Hospital Regional Cancer Centre, The University of Ottawa, Ottawa, Canada
J Clin Oncol 24:2673-8. 2006..There is a need for a determined, coordinated effort to conduct high-quality clinical trials in patients with these rare cancers...
Cancer of the oropharynxLisa Licitra
START Project, European School of Oncology, Viale Beatrice d'Este, 37, 20122 Milan, Italy
Crit Rev Oncol Hematol 41:107-22. 2002..Acute toxicity needs to be managed promptly. Late sequelae are less known. Treatment of such tumours requires a multidisciplinary approach within experienced centres...
Folate in head and neck squamous cell cancer chemoprevention: purposely left out?Paolo Bossi
J Clin Oncol 26:3463; author reply 3463-4. 2008
Motesanib diphosphate in progressive differentiated thyroid cancerSteven I Sherman
Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas M D Anderson Cancer Center, Houston 77230 1402, USA
N Engl J Med 359:31-42. 2008..Motesanib diphosphate (AMG 706) is a novel oral inhibitor of VEGF receptors, platelet-derived growth-factor receptor, and KIT...
